This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to
understand the utility of empagliflozin in worsening heart failure (HF) patients with or
without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks,
followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.